Drugs that contain Tobramycin
1. Bethkis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7939502 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Jun, 2022
(1 year, 10 months ago) | |
| US6987094 | CHIESI | Optimized formulation of tobramycin for aerosolization |
Sep, 2022
(1 year, 6 months ago) | |
| US7696178 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Sep, 2022
(1 year, 6 months ago) | |
Market Authorisation Date: 12 October, 2012
Treatment: Management of cystic fibrosis patients
Dosage: SOLUTION;INHALATION
BETHKIS family patents
2. Tobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5508269 | MYLAN SPECIALITY LP | Aminoglycoside formulation for aerosolization |
Oct, 2014
(9 years ago) | |
Market Authorisation Date: 22 December, 1997
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: SOLUTION;INHALATION
TOBI family patents
3. Tobi Podhaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7097827 | MYLAN SPECIALITY LP | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
Apr, 2016
(8 years ago) | |
| US7442388 | MYLAN SPECIALITY LP | Phospholipid-based powders for drug delivery |
May, 2020
(3 years ago) | |
| US8349294 | MYLAN SPECIALITY LP | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
May, 2020
(3 years ago) | |
| US7368102 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycosides |
Dec, 2022
(1 year, 4 months ago) | |
| US9421166 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(1 year, 4 months ago) | |
| US8715623 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(1 year, 4 months ago) | |
| US7516741 | MYLAN SPECIALITY LP | Aerosolization apparatus with feedback mechanism |
Jan, 2024
(3 months ago) | |
| USRE47526 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Apr, 2024
(10 days ago) | |
| US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(5 months from now) | |
| US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(6 months from now) | |
| US8664187 | MYLAN SPECIALITY LP | Methods of treatment of endobronchial infections |
Jun, 2025
(1 year, 2 months from now) | |
| US7559325 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Oct, 2025
(1 year, 6 months from now) | |
| US8869794 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncturing member |
Sep, 2028
(4 years from now) | |
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents